NO942178L - - Google Patents

Info

Publication number
NO942178L
NO942178L NO942178A NO942178A NO942178L NO 942178 L NO942178 L NO 942178L NO 942178 A NO942178 A NO 942178A NO 942178 A NO942178 A NO 942178A NO 942178 L NO942178 L NO 942178L
Authority
NO
Norway
Prior art keywords
group
carbon atoms
production
hydrocarbon radical
hydrogen atom
Prior art date
Application number
NO942178A
Other languages
English (en)
Norwegian (no)
Other versions
NO305949B1 (no
NO942178D0 (no
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO942178L publication Critical patent/NO942178L/no
Publication of NO942178D0 publication Critical patent/NO942178D0/no
Publication of NO305949B1 publication Critical patent/NO305949B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO942178A 1991-12-13 1994-06-10 20-metylsubstituerte vitamin D-derivater, farmasoeytiske preparater inneholdende disse, og anvendelse derav NO305949B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4141746A DE4141746A1 (de) 1991-12-13 1991-12-13 20-methyl-substituierte vitamin d-derivate
PCT/EP1992/002887 WO1993012081A1 (de) 1991-12-13 1992-12-14 20-methyl-substituierte vitamin d-derivate

Publications (3)

Publication Number Publication Date
NO942178L true NO942178L (cs) 1994-06-10
NO942178D0 NO942178D0 (no) 1994-06-10
NO305949B1 NO305949B1 (no) 1999-08-23

Family

ID=6447341

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942178A NO305949B1 (no) 1991-12-13 1994-06-10 20-metylsubstituerte vitamin D-derivater, farmasoeytiske preparater inneholdende disse, og anvendelse derav

Country Status (24)

Country Link
US (1) US5446035A (cs)
EP (1) EP0637299B1 (cs)
JP (1) JP3280975B2 (cs)
KR (1) KR100271462B1 (cs)
CN (1) CN1035177C (cs)
AT (1) ATE138366T1 (cs)
AU (1) AU670585B2 (cs)
CA (1) CA2125476C (cs)
CZ (1) CZ286579B6 (cs)
DE (2) DE4141746A1 (cs)
DK (1) DK0637299T3 (cs)
ES (1) ES2089585T3 (cs)
FI (1) FI108226B (cs)
GR (1) GR3020097T3 (cs)
HU (1) HUT68263A (cs)
IL (1) IL104074A (cs)
MX (1) MX9207101A (cs)
NO (1) NO305949B1 (cs)
NZ (1) NZ246052A (cs)
PL (1) PL171403B1 (cs)
SK (1) SK280450B6 (cs)
TW (1) TW275060B (cs)
WO (1) WO1993012081A1 (cs)
ZA (1) ZA929650B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220272D0 (en) * 1992-09-25 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US20040167106A1 (en) * 1993-06-04 2004-08-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of a Vitamin D compound
GB9315253D0 (en) * 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
ES2243978T3 (es) * 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
DE19619036A1 (de) 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
SG70010A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Fluorinated vitamin d3 analogs
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) * 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
DE69814109T2 (de) * 1997-09-08 2004-02-26 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US6443856B1 (en) 1999-11-01 2002-09-03 Callaway Golf Company Contoured scorelines for the face of a golf club
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1314427A4 (en) * 2000-08-17 2006-05-03 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR THE TREATMENT OF OSTEOPOROSIS
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
NZ563270A (en) * 2005-05-10 2010-11-26 Dermipsor Ltd Calcipotriol, polyethylene oxide topical compositions for the treatment of hyperproliferative epidermal diseases
EP1879449A4 (en) * 2005-05-10 2009-12-16 Dermipsor Ltd SKIN CARE COMPOSITIONS AND METHODS
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ, インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
PL1734251T3 (pl) * 2005-06-17 2007-05-31 Magneti Marelli Powertrain Spa Wtryskiwacz paliwa
AU2007287263A1 (en) * 2006-04-10 2008-02-28 Wisconsin Alumni Research Foundation Lalpha-hydroxy-2- (3 ' -hydroxypropylidene) -19-nor- vitamin D compounds with a 1,1-dimethylpropyl side chain
CA2838089A1 (en) 2006-08-25 2008-02-28 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
US20100196308A1 (en) * 2009-01-27 2010-08-05 Jimenez Joaquin J Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
SG10201404883YA (en) 2009-08-14 2014-10-30 Berg Llc Vitamin d3 and analogs thereof for treating alopecia
US20190183908A1 (en) 2016-05-13 2019-06-20 Case Western Reserve University Autophagy activators for treating or preventing skin injury
AU2017302660B2 (en) 2016-07-29 2023-04-20 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US11903952B2 (en) 2020-05-27 2024-02-20 Northwestern University Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection

Also Published As

Publication number Publication date
AU670585B2 (en) 1996-07-25
CN1035177C (zh) 1997-06-18
FI942766A7 (fi) 1994-06-10
JPH07505132A (ja) 1995-06-08
CA2125476A1 (en) 1993-06-24
ATE138366T1 (de) 1996-06-15
AU4035693A (en) 1993-07-19
CN1073677A (zh) 1993-06-30
ES2089585T3 (es) 1996-10-01
SK280450B6 (sk) 2000-02-14
EP0637299B1 (de) 1996-05-22
HU9401456D0 (en) 1994-08-29
IL104074A0 (en) 1993-05-13
FI942766A0 (fi) 1994-06-10
KR100271462B1 (ko) 2000-11-15
DE59206393D1 (de) 1996-06-27
NZ246052A (en) 1995-07-26
ZA929650B (en) 1993-06-09
WO1993012081A1 (de) 1993-06-24
IL104074A (en) 1998-01-04
US5446035A (en) 1995-08-29
EP0637299A1 (de) 1995-02-08
DK0637299T3 (da) 1996-09-30
JP3280975B2 (ja) 2002-05-13
NO305949B1 (no) 1999-08-23
HUT68263A (en) 1995-06-28
CZ141694A3 (en) 1995-01-18
TW275060B (cs) 1996-05-01
CZ286579B6 (cs) 2000-05-17
FI108226B (fi) 2001-12-14
SK66194A3 (en) 1995-02-08
DE4141746A1 (de) 1993-06-17
MX9207101A (es) 1993-08-01
PL171403B1 (pl) 1997-04-30
NO942178D0 (no) 1994-06-10
CA2125476C (en) 2003-02-11
KR940703806A (ko) 1994-12-12
GR3020097T3 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
TW275060B (cs)
EP0648207A1 (en) VITAMIN D DERIVATE.
ZA858169B (en) New adamantanamine derivatives,processes for their preparation and drugs in which they are present
IL69230A (en) 6,16-dimethyl corticoids,process for the preparation thereof and pharmaceutical compositions containing the same
ES2098403T3 (es) Derivados de la imidazoindolizina y procedimiento para su preparacion.
ES464728A1 (es) Procedimiento para producir derivados del acido propionico
ES2072765T3 (es) Procedimiento para la obtencion de 5,6-dihidroxi-indolinas.
DE69415812D1 (de) 15,15-dialkylsubstituierte östradiolderivate
IL64614A (en) 6alpha-methylhydrocortisone derivatives,processes for their preparation and pharmaceutical compositions containing them
AU563426B2 (en) 3-alkoxy-2(n-pyrrolidino)-n-pyridyl-n-furyl (or thienyl) methyl propylamines
HUT35658A (en) Process for producing 7-oxo-prostacycline derivatives of selective biological activity
TW252976B (cs)
SI0746556T1 (en) Tricyclic compounds having affinity for the 5-ht1a receptor
GB1416929A (en) Fluoranthene derivatives
ES8200703A1 (es) Procedimiento para la preparacion de 1-hidroxi-esteroides
ES2085544T3 (es) Procedimiento para la fabricacion de 8-n,n-dialquilaminotriciclo-(5.2.1.02,6)decano.
ES2059702T3 (es) Politioureas, procedimiento para su fabricacion y empleo de estas politioureas para evitar o reducir la formacion de costras en reactores.